Progesterone Receptor (Ser294) Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bsm-70232M |
| Product Name | Progesterone Receptor (Ser294) Antibody |
| Applications |
WB
IHC
|
| Specificity | Specific for endogenous levels of the ~90 kDa PR-A isoform and the ~120 kDa PR-B isoform phosphorylated at Ser294. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide. |
| Reactivity | Human |
| Predicted Reactivity | Non-Human Primate |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Mouse |
| Source | Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser294 of human progesterone receptor, conjugated to keyhole limpet hemocyanin (KLH). |
| Modification Site | Ser294 |
| Clonality | Monoclonal |
| Clone # | 608 |
| Isotype | IgG1 |
| Concentration | Lot Dependent |
| Purification | Purified by Protein G. |
| Storage Buffer | 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage Condition | Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target | |
| Gene ID | 5241 |
| Swiss Prot | P06401 |
| Synonyms | NR3C3 antibody, Nuclear receptor subfamily 3 group C member 3 antibody, PGR antibody, PR antibody, PRA antibody, PRB antibody, PRGR_HUMAN antibody, Progesterone receptor antibody, Progestin receptor form A antibody, Progestin receptor form B antibody |
| Background | There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser-190 and Ser-294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor. |
| Application Dilution | |
| WB | 1:300-5000 |
| IHC | |